The Immutep Ltd (ASX: IMM) share price is climbing in late-morning trade after announcing a new European patent grant. Here’s all the details.
The post Here’s why the Immutep (ASX:IMM) share price is climbing today appeared first on The Motley Fool Australia. –
The Immutep Ltd (ASX: IMM) share price is climbing in late-morning trade after announcing a new European patent grant. At the time of writing, the biotechnology company’s shares are swapping hands for 44 cents, up 2.35%.
What was announced?
Investors are pushing Immutep shares higher after digesting the company’s positive update.
According to its release, Immutep advised that it has been granted a patent to add to its portfolio. Approved by the European Patent Office, the latest addition will seek to further protecting Immutep’s intellectual property.
The new patent is titled, ‘Combination therapies comprising antibody molecules to LAG-3’ (patent number EP3317301).
Immutep stated that the patent discusses LAG525, a humanised form of its IMP701 antibody. This is out-licensed to Novartis AG. The new patent also explains how to use LAG525 and spartalizumab. This is an anti-PD-1 antibody molecule that can be used to treat cancer patients.
Developed by Immutep, IMP701 is a therapeutic antibody previously used to target LAG-3. The antibody works in controlling the signalling pathways, activating T cell function. Thus, it removes two brakes to allow the immune system to kill cancer cells.
Immutep noted that rights to the development and commercialisation of IMP701 are exclusively licensed to Novartis. Currently, LAG525 is being evaluated in several trials by Novartis in combination with its PD-1 inhibitor spartalizumab. In addition, Immutep is eligible to receive development-based milestone payments and sales-based royalties on achieving its agreed targets.
The EP3317301 patent is also jointly owned by Novartis and Immutep, and is set to expire on 28 July 2036.
Immutep share price review
In the past 12 months, the Immutep share price has gained 250%, with most of those gains coming in 2020. Year-to-date, the company’s shares are up just 5% after recording heavy selling during March.
On valuation grounds, Immutep has a market capitalisation of roughly $292.4 million, with 672.3 million shares outstanding.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
- Why Immutep, Inghams, REA Group, & Synlait shares are sinking
- Why the Immutep (ASX:IMM) share price is rocketing 39% higher today
- Why the Immutep (ASX:IMM) share price is up 6% today
- Why the Immutep (ASX:IMM) share price will be in focus today
Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.